Point of Care (POC) Immunoassay Analyzer Expansion Market Report 2026

The point of care (POC) immunoassay analyzer expansion market size has grown strongly in recent years. It will grow from $4.9 billion in 2025 to $5.31 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, growth of hospital laboratory infrastructure, increasing demand for rapid diagnostics, expansion of immunoassay technology adoption, improvements in antibody and antigen detection methods.

The point of care (POC) immunoassay analyzer expansion market size is expected to see strong growth in the next few years. It will grow to $7.45 billion by 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to expansion of personalized medicine and biomarker-based testing, increasing shift toward decentralized healthcare delivery, rising adoption of ai-enabled diagnostic systems, growth in home-based healthcare monitoring, increasing regulatory approvals for rapid diagnostic devices. Major trends in the forecast period include expansion of decentralized point-of-care diagnostic ecosystems, increasing adoption of multiplex immunoassay platforms, integration of wireless connectivity in portable analyzers, growth of cartridge-based rapid testing systems, rising demand for at-home immunodiagnostic solutions.

The increasing prevalence of infectious diseases is expected to propel the growth of the point of care immunoassay analyzer expansion market going forward. Infectious diseases are medical conditions caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi that spread directly or indirectly between individuals. The increasing prevalence of infectious diseases is driven by rising global population density, which accelerates transmission risks and the spread of diseases. Point of care (POC) immunoassay analyzer expansion supports the management of infectious diseases by enabling rapid, accurate, and decentralized detection of infectious biomarkers, thereby strengthening early diagnosis and disease control efforts. For instance, in March 2025, according to the UK Health Security Agency, a UK-based government health authority, tuberculosis cases in England increased by 13% in 2024, reaching 5,480 cases compared to 4,850 cases in 2023. Therefore, the increasing prevalence of infectious diseases is driving the growth of the point of care immunoassay analyzer expansion market.

Leading companies operating in the point of care immunoassay analyser expansion market are concentrating on developing innovative solutions, such as advancements in immunoassay technologies, to address the growing demand for rapid diagnostics, decentralized healthcare, and real-time clinical decision-making in emergency and remote settings. These advanced immunoassay analyzers are compact diagnostic platforms that use antigen-antibody reactions to detect biomarkers with high sensitivity, offering capabilities such as rapid turnaround times, portability, minimal sample preparation, and multiplex testing functions; unlike conventional centralized laboratory analyzers that require sophisticated infrastructure and longer processing durations, POC systems facilitate near-patient testing with faster results and greater accessibility. For instance, in July 2023, Anbio Biotechnology launched the AF-100S Fluorescence Immunoassay Analyzer. This system is a compact, automated fluorescent immunoassay analyzer developed for rapid quantitative detection of biomarkers in clinical samples such as whole blood, serum, and plasma. It combines fluorescence-based detection technology with automated calibration and integrated quality control to ensure high sensitivity and accuracy comparable to centralized laboratory systems. Additionally, the analyzer includes a user-friendly interface and delivers test results within minutes, making it highly suitable for emergency departments, clinics, and decentralized healthcare environments.

In August 2024, Roche acquired LumiraDx point-of-care technology assets for an undisclosed amount. Through this acquisition, Roche aims to strengthen its diagnostics portfolio by integrating LumiraDx’s innovative point-of-care testing platform, which includes immunoassay-based diagnostic capabilities, and expanding its presence in decentralized healthcare solutions. LumiraDx is a UK-based diagnostics company specializing in rapid point-of-care testing technologies.

Major companies operating in the point of care (poc) immunoassay analyzer expansion market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, Becton, Dickinson and Company (BD), Beckman Coulter, Bruker Corporation, BioRad Laboratories, Qiagen N. V., Diasorin, Lepu Medical Technology, SD Biosensor, Eiken Chemical Co. Ltd., Molbio Diagnostics Pvt. Ltd., Maccura Biotechnology Co. Ltd., QuantuMDx Group Ltd., Ustar Biotechnologies Ltd., Mylab Discovery Solutions Pvt Ltd., Akonni Biosystems Inc., Zeesan Biotech Co. Ltd.

North America was the largest region in the point-of-care immunoassay analyzer expansion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point of care (POC) immunoassay analyzer expansion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the point of care (POC) immunoassay analyzer expansion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The point-of-care immunoassay analyzer expansion market consists of revenues earned by entities by providing services such as analyzer installation, calibration, maintenance, cloud-based data connectivity, software integration, remote monitoring, and consumable supply services. The market value also includes the value of related goods sold by the service provider or included within the service offering. The point-of-care immunoassay analyzer expansion market also includes sales of POC immunoassay analyzers, peripheral devices, biosensors, handheld analyzers, automated test systems, sample preparation devices, and associated accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream healthcare providers, distributors, or retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.